TARABEN 54Y /F K/C/O PLHV SINCE 1.5 MONTHS A/W ORAL CANDIDIASIS + AKI + COAGULOPATHY+ UREMEIC ENCEPHALOPATHY C/O DIFFICULTY IN SWALLOWING(SOLIDS>LIQUIDS) SINCE 20 DAYS NO C/O CHANGE OF VOICE, DIFFICULTY IN BREATHING, THROAT PAIN H/O FEVER+, LOSS OF APPETITE CURRENT LABS PT/INR/APTT-25.4/1.89/45.2 LFT-ALBUMIN-1.8 REST NORMAL URINE RM -PROTEIN +1 NO BLOOD 8/05/26 RFT-222/6/143/4.11 POST HD -87/3.19/144/3.12 FERRITIN-787 IRON-37 TIBC-158 RETIC-1.8% CRP-106 08/05/26-CBC-8/2.2/130 MCV-88.4 HCT-29.1 NLE-70/25/1 10/05/26-CBC-6.3/1.51/128 MCV84.7 HCT-21.4 NLE-82/14/1 PS-NORMOCYTIC NORMOCHROMIC RBCS WITH ANISOPOIKILOCYTOSIS(+) FEW MACROCYES AND FEW OVALOCYTES ARE SEEN. REFER FOR PANCYTOPNEIA what should be next step
Reading File
Finding Sources
Finding Sources
Searching PubMed
pancytopenia HIV evaluation bone marrow
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Now I have enough information. Let me synthesize a comprehensive, clinically actionable response.
Taraben – 54F | K/C/O PLHV (Presumed HIV) | Pancytopenia Workup
Clinical Context Summary
| Parameter | Value | Interpretation |
|---|---|---|
| Hb | 8 → 6.3 g/dL (dropping) | Significant anaemia, worsening |
| TLC | 2.2 → 1.51 × 10³ | Leukopenia, worsening |
| Platelets | 130 → 128 × 10³ | Borderline thrombocytopenia |
| NLE | 70/25 → 82/14/1 | Neutrophilia with lymphopenia (reversed) |
| MCV | 88.4 → 84.7 | Normocytic (not megaloblastic) |
| Retic | 1.8% | Low-normal — suggests inadequate marrow response |
| Ferritin | 787, Iron 37, TIBC 158 | Ferritin elevated (acute phase / chronic inflammation), functional iron deficiency |
| CRP | 106 | Significant systemic inflammation |
| Albumin | 1.8 | Severe hypoalbuminaemia — hepatic synthetic failure / malnutrition |
| INR | 1.89 | Coagulopathy — hepatic |
| RFT | AKI (post-HD improved) | — |
| PS | Normocytic normochromic + anisopoikilocytosis, macrocytes, ovalocytes |
This is a pancytopenia in an immunocompromised (likely advanced HIV) patient with multi-organ involvement (liver, kidney, CNS). Pancytopenia here is almost certainly multifactorial.
Differential Diagnosis for Pancytopenia in This Patient
Tier 1 — Must Rule Out First (Life-threatening / Treatable)
| Cause | Why Suspect |
|---|---|
| Disseminated opportunistic infection (MAC, Histoplasma, Leishmania, CMV, Cryptococcus) | Advanced HIV + fever + hepatosplenomegaly likely + pancytopenia; bone marrow infiltration is classic |
| Myelodysplastic syndrome (MDS) | Age 54, ovalocytes on PS, cytopenias; must exclude |
| HIV-associated myelosuppression | Direct HIV effect on hematopoietic progenitors; late disease |
| Drug-induced marrow suppression | Any recent ART (especially AZT), fluconazole (can cause marrow suppression), co-trimoxazole |
Tier 2 — Likely Contributing
| Cause | Why Suspect |
|---|---|
| Anaemia of chronic disease / inflammation | CRP 106, ferritin 787, low TIBC — classic pattern |
| Nutritional deficiency | Albumin 1.8, dysphagia 20 days → B12/folate deficiency (explains macrocytes + ovalocytes) |
| Hypersplenism (portal hypertension if cirrhotic) | Liver disease + low albumin + coagulopathy |
| Uraemia-related marrow suppression | Pre-HD RFT creatinine 222 |
| Aplastic anaemia (secondary, viral/drug-induced) | Possible but less likely given PS morphology |
Next Steps — Systematic Workup
IMMEDIATE (Do Today)
-
Bone Marrow Aspirate + Biopsy (BMA/BMB) ← This is the single most important next step
- Indicated: severe pancytopenia + worsening counts + immunocompromised host
- Send for: morphology, cellularity, special stains (ZN, PAS, GMS for fungi, Leishmania LD bodies), flow cytometry (to exclude lymphoma/blast crisis), culture (bacterial + fungal + AFB)
- Per Harrison's 22E: "Severe pancytopenia" is a primary indication for bone marrow examination
- Per Goldman-Cecil: Aplastic anaemia is a diagnosis of exclusion requiring BMA + BMB
-
Check current ART regimen — is she on Zidovudine (AZT)? AZT is a major cause of macrocytic anaemia and bone marrow suppression; switch to TDF/3TC-based regimen if confirmed
-
CD4 count + HIV viral load — assess stage of immunosuppression; guides OI prophylaxis
URGENT LABS (Within 24–48 hrs)
| Test | Purpose |
|---|---|
| Serum B12 + Folate | Macrocytes + ovalocytes + dysphagia → likely deficient; B12 can cause pancytopenia |
| LDH + uric acid | Haemolysis screen; also elevated in lymphoma, infiltration |
| Peripheral blood film — expert review | Confirm no blasts, dysplastic features, LD bodies |
| Serum protein electrophoresis | Exclude myeloma |
| Reticulocyte absolute count | Confirms hypoproduction |
| Lactate | Metabolic status |
| Procalcitonin | Sepsis workup |
| Blood cultures (aerobic + anaerobic + fungal) | Active disseminated infection |
| Serum Cryptococcal Ag | Common in advanced HIV with CNS involvement (she has encephalopathy) |
| CMV PCR / EBV PCR | Viral marrow suppression |
| Serum Histoplasma / Aspergillus Ag | Endemic fungi |
| Coombs (DAT) | Immune haemolysis |
IMAGING
| Test | Purpose |
|---|---|
| USG Abdomen | Hepatomegaly, splenomegaly, portal HTN, lymphadenopathy |
| CECT Abdomen + Chest (if renal function allows post-HD) | Lymphoma staging, OI foci |
MANAGEMENT WHILE AWAITING
- Stop AZT if on it — replace with non-myelosuppressive ART (TDF/ABC + 3TC + EFV/DTG)
- Blood transfusion: Hb 6.3 → Transfuse to Hb ≥8 g/dL (PRBC), especially with AKI and encephalopathy
- FFP / Vitamin K for coagulopathy (INR 1.89) if bleeding risk
- Nutritional support: IV/NG nutrition + IV B12 (1000 mcg IM daily × 7 days) + folic acid 5 mg OD (start empirically given dysphagia 20 days + albumin 1.8)
- Fluconazole for oral candidiasis — but note fluconazole can worsen cytopenias; monitor
- OI prophylaxis: Co-trimoxazole prophylaxis (hold if TLC very low; use pentamidine nebuliser as alternative)
Summary Algorithm
Pancytopenia in HIV+ patient
↓
1. Stop myelosuppressive drugs (esp. AZT)
2. BMA + BMB → morphology + culture + special stains
3. B12/Folate levels → replace empirically
4. Serum CrAg + CMV/EBV PCR + fungal Ag
5. USG abdomen (splenomegaly/portal HTN)
6. CD4 + VL → guide ART + OI prophylaxis
7. Blood transfusion support
8. Nutritional rehabilitation
Bottom line: The bone marrow aspirate and biopsy is the most critical next step — it will identify marrow infiltration by opportunistic organisms (MAC, Histoplasma, Leishmania), aplasia, dysplasia, or lymphoma, all of which are common in advanced HIV and directly determine treatment. Simultaneously replace B12/folate empirically, stop any AZT, and send OI serology.
— Goldman-Cecil Medicine (International Edition); Harrison's Principles of Internal Medicine 22E
Can uremia cause pancytopenia
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Excellent — I now have enough from authoritative sources to give a complete answer.
Does Uraemia Cause Pancytopenia?
Short answer: Not true pancytopenia in the classical sense — but uraemia significantly affects all three cell lines through distinct mechanisms.
Here is what the evidence says lineage by lineage:
1. Anaemia ✅ (Primary and Well-Established)
Uraemia causes anaemia through multiple concurrent mechanisms:
| Mechanism | Detail |
|---|---|
| ↓ Erythropoietin (EPO) production | Dominant cause — damaged kidneys fail to synthesise adequate EPO → inadequate red cell production |
| Reduced RBC lifespan / haemolysis | Uremic toxins reduce RBC survival through uncertain mechanisms → extravascular haemolysis |
| Platelet dysfunction → bleeding → iron deficiency | Chronic blood loss leads to eventual iron deficiency anaemia on top |
| Direct marrow suppression | Uremic toxins suppress erythroid progenitors |
This is normocytic normochromic initially, and tends to be proportional to the severity of uraemia.
"The basis of anemia in renal failure is multifactorial, but the dominant cause is the diminished synthesis of erythropoietin by the damaged kidneys, leading to inadequate red cell production." — Robbins & Cotran Pathologic Basis of Disease
2. Platelet Dysfunction ✅ (Qualitative, Not Quantitative)
This is the most important white flag — uraemia causes:
- Platelet dysfunction (thrombasthenia), NOT thrombocytopenia
- Elevated bleeding time
- Diminished aggregation to ADP and epinephrine
- Reduced ristocetin-induced platelet agglutination
- Impaired platelet–endothelium interaction
"The function of platelets is often impaired (thrombasthenia), whereas the number of circulating platelets is generally normal... The platelet itself is not abnormal in uremia; rather the interaction of platelets with the vascular endothelium is impaired." — Brenner & Rector's The Kidney
So in your patient: INR 1.89 + coagulopathy is from liver disease (albumin 1.8), NOT uraemia alone. Uraemia adds platelet functional impairment on top.
3. Leukopenia ❌ (Not a Direct Effect of Uraemia)
- Uraemia does not directly cause leukopenia or neutropenia
- Uraemic patients have impaired neutrophil function (chemotaxis, phagocytosis) → increased infection susceptibility
- Actual low WBC count in uraemia is NOT expected and should prompt a search for another cause
"Impaired host immunity has been described in ESKD and may be operative in severe AKI." — Harrison's 22E
Applying This to Taraben
| Cell Line | Uraemia's Role | Other Cause to Consider |
|---|---|---|
| Hb 6.3 | Partial contributor (EPO deficiency, haemolysis) | ACD, HIV myelosuppression, AZT, nutritional (B12/folate), blood loss |
| Platelets 128 | Functional impairment, count normal | Mild hypersplenism, HIV, liver disease |
| WBC 1.51, NLE 82/14 | NOT due to uraemia | HIV/AIDS myelosuppression, opportunistic infection (bone marrow infiltration), drug-induced |
Practical Point
Uraemia alone does NOT cause true pancytopenia (depression of all three cell lines by count). It causes:
- Anaemia (yes — EPO deficiency + haemolysis)
- Platelet dysfunction (yes — qualitative only)
- WBC count reduction (no — requires another explanation)
In Taraben's case, the falling WBC and worsening Hb despite HD strongly argues for a cause beyond uraemia — most likely advanced HIV-related marrow suppression, opportunistic infection, or AZT toxicity — and the bone marrow biopsy remains essential.
— Robbins & Cotran Pathologic Basis of Disease; Brenner & Rector's The Kidney; Harrison's Principles of Internal Medicine 22E
Search for recent guidelines on managing anaemia in HIV with renal failure y female
Reading File
Searching PubMed
anaemia HIV chronic kidney disease management guidelines
Searching the Web
anaemia management HIV renal failure guidelines 2023 2024 erythropoietin
Reading Web Page
anaemia HIV renal failure CKD management iron ESA transfusion targets
Searching PubMed
anemia HIV infection treatment erythropoietin iron supplementation
Finding Sources
Reading File
Searching PubMed
anemia HIV chronic kidney disease erythropoiesis stimulating agent
Searching the Web
WHO HIV anaemia management guidelines 2024 iron supplementation renal failure hemodialysis
Reading Web Page
anemia management HIV CKD hemodialysis iron ESA epoetin guidelines India
Searching PubMed
anemia HIV ESKD hemodialysis outcomes treatment
Now let me also quickly read Taraben's discharge sheet to incorporate her specific values.
The image shows:
- Hb: On admission 6.5, on discharge 6.8 (earlier records show 8→6.3 from CBC)
- HIV: Confirmed positive (HIV+ve noted)
- HBsAg: −ve
- B12: >21 µg/d (Vit B12 → 21.0 µg/d — this appears elevated or replete)
- S. Ferritin: 12.0 µg/d (likely 12 = ferritin 12 — this is LOW, contradicting the earlier 787)
- TSH: <0.06 (suppressed — possible hyperthyroidism contributing to anaemia/high output)
- PT/INR: 12.2/1.13 → 11.2/0.94 (improved)
- BMA + Bone Biopsy: Done — cytogenetics = normal; RBC type III; Mononuclear: 15-19/1; Megakaryocyte II: 0.14-7
- PC-1 2.0↑, CLL 0.60↑, JNPC-we, PLHV negative? — (HIV PCL confirmed; HPLC for beta)
- Treatment: IV iron given, Darbepoetin 1 µg in 100 cc over OD
This is very helpful — BMA was already done, cytogenetics normal, and Darbepoetin (ESA) has been started, IV iron given. Now I have full context.
Recent Guidelines: Anaemia in HIV + Renal Failure (Female, on HD)
Reading Taraben's Discharge Sheet
From the image I can confirm:
- BMA/BMB done → Cytogenetics normal → rules out MDS, marrow infiltration
- Darbepoetin already initiated (1 µg IV in 100 mL OD) ✅
- IV iron given ✅
- TSH < 0.06 → Subclinical/overt hyperthyroidism — this is an additional contributor to anaemia and high-output state
- S. Ferritin 12 → True absolute iron deficiency (ferritin 787 was an acute-phase reactant, not reflective of stores; now that inflammation resolved, true ferritin = 12) ✅ confirms iron deficiency
- B12 → 21 — may represent B12 level in normal range; supplementation appears underway
Current Guidelines Summary (2025–2026)
1. KDIGO 2026 Anaemia in CKD — Latest Comprehensive Update
| Recommendation | Detail |
|---|---|
| Define anaemia | Hb <12 g/dL in women (WHO threshold) |
| Identify reversible causes first | Iron deficiency, B12/folate, thyroid, inflammation, drug-induced — before starting ESA |
| Iron supplementation | IV iron preferred over oral in HD patients (superior Hb response, lower ESA dose) |
| Iron targets (dialysis patients) | Ferritin target 200–500 µg/L; TSAT 20–40% |
| Iron in HIV | Ferritin unreliable in HIV (acute-phase reactant) — use soluble transferrin receptor (sTfR) or TSAT <20% to confirm deficiency |
| ESA initiation threshold | Hb 8.5–10.0 g/dL for most dialysis patients |
| ESA Hb target | 10–11.5 g/dL (avoid >13 g/dL — increases stroke, vascular access thrombosis risk) |
| Transfusion | Restrictive strategy — use only for symptomatic severe anaemia or if ESA/iron insufficient |
Source: KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD (Kidney Int 2026)
2. HIV-Specific Guidance (HIVMA / DHHS / Clinical Nephrology)
| Situation | Recommendation |
|---|---|
| AZT-induced anaemia | Switch to non-myelosuppressive ART (TDF/TAF + 3TC + DTG/EFV). Epoetin indicated for AZT anaemia if Hb <10 g/dL & serum EPO ≤500 mU/mL |
| HIV + ESKD on HD | EPO/Darbepoetin response is comparable to HIV-negative dialysis patients — treat the same way |
| Ferritin interpretation in HIV | Ferritin often falsely elevated (acute-phase protein); sTfR or TSAT <20% is more reliable |
| ART dosing in renal failure | Avoid TDF in advanced CKD (nephrotoxic); prefer TAF, Abacavir (ABC), DTG, EFV (no dose adjustment needed); most NRTIs need dose reduction in HD |
| Nutritional | B12, folate supplementation; nutritional rehabilitation critical |
Source: Comprehensive Clinical Nephrology 7th Ed; DHHS Guidelines for HIV in Renal Disease
3. Indian Society of Nephrology (ISN India) Consensus 2024
(Specifically relevant for Taraben at SVPIMSR, Ahmedabad)
| Parameter | Recommendation |
|---|---|
| ESA initiation | When Hb <10 g/dL |
| Target Hb | 10–12 g/dL |
| Short-acting EPO alpha/beta dose | 80–120 U/kg 2–3×/week SC/IV |
| Darbepoetin (long-acting) | Preferred for compliance; 1 µg = ~200 IU EPO (30% dose reduction vs EPO) |
| IV iron in HD | Iron sucrose, ferric carboxymaltose, ferric gluconate — give during or after dialysis session |
| Monitor Hb | Every 2–4 weeks; if Hb rises >2 g/dL/month → reduce ESA dose by 25% |
| Upper safety limit | Do NOT target Hb >12 g/dL — cardiovascular/thrombotic risk |
| HIF-PHI (Roxadustat) | Alternative to ESA, especially when ESA resistance; caution in HIV (drug interactions with ART) |
Source: Indian Journal of Nephrology – ISN India Consensus Guidelines 2024
Applied to Taraben
| Issue | Action |
|---|---|
| Hb 6.3–6.8 g/dL, on HD, HIV+ | Darbepoetin started ✅ — correct per all guidelines |
| Ferritin 12 (true iron deficiency confirmed) | IV iron started ✅ — preferred route in HD patients |
| TSH <0.06 (hyperthyroid) | NEW finding — check free T3/T4; treat hyperthyroidism (propranolol/methimazole) — contributes to high-output anaemia |
| BMA normal cytogenetics | No MDS/infiltration — EPO response expected to be good |
| ART regimen | Verify she is NOT on AZT — if on AZT, switch to TAF/ABC-based regimen |
| Hb target | Aim 10–11 g/dL — not higher in HIV+CKD |
| Monitor | CBC every 2–4 weeks; TSAT/ferritin monthly; sTfR more reliable than ferritin in HIV |
| B12 | If B12 level low (the 21 on sheet needs unit clarification — if pmol/L may be low) → continue supplementation |
Key takeaway: The treatment already started (Darbepoetin + IV iron) is guideline-concordant per KDIGO 2026, ISN India 2024, and HIV nephrology evidence. The newly identified suppressed TSH (<0.06) should be investigated as a separate contributor — thyroid disease is common in HIV and causes or worsens anaemia. ART review to exclude AZT is essential.
Sources: KDIGO 2026 Anaemia in CKD Guideline; ISN India Consensus 2024 (Indian J Nephrology); Comprehensive Clinical Nephrology 7th Ed; DHHS HIV Guidelines
Only make short summary
Anaemia in HIV + Renal Failure (Female on HD) — Guidelines Summary
Diagnosis threshold: Hb <12 g/dL in women (WHO/KDIGO 2026)
Step 1 — Fix reversible causes first
- Correct iron deficiency (use TSAT <20%, not ferritin — unreliable in HIV)
- Replace B12/folate
- Review ART — stop AZT if present, switch to TAF/ABC + DTG
Step 2 — Iron
- IV iron preferred over oral in HD patients
- Target: Ferritin 200–500 µg/L, TSAT 20–40%
Step 3 — ESA (Erythropoietin/Darbepoetin)
- Start when Hb <10 g/dL
- Target Hb: 10–11.5 g/dL (never exceed 12–13 — stroke/clot risk)
- HIV+ on HD responds to EPO same as HIV-negative patients
- Darbepoetin preferred (less frequent dosing, better adherence)
Step 4 — Transfusion
- Restrictive strategy — only if symptomatic severe anaemia or ESA/iron insufficient
For Taraben specifically:
- Darbepoetin + IV iron already started ✅ — guideline-concordant
- TSH <0.06 → investigate hyperthyroidism (additional contributor)
- Verify no AZT in ART regimen
KDIGO 2026 | ISN India 2024 | Comprehensive Clinical Nephrology 7th Ed
This is a shared conversation. Sign in to Orris to start your own chat.